RBFC
HALO icon

Roman Butler Fullerton & Co’s Halozyme HALO Stock Holding History

Roman Butler Fullerton & Co’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,751
Closed -$414K – 254
2025
Q1 		$414K Buy
+6,751
New +$392K 0.16% 142

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Roman Butler Fullerton & Co's HALO Position: Q2 2025 in Review

Roman Butler Fullerton & Co sold out of Halozyme (HALO) in Q2 2025, closing a stake of 6,751 shares — an estimated $414K sold.

Roman Butler Fullerton & Co first reported a position in HALO in Q1 2025 and held it in 1 quarter. The position peaked at $414K in Q1 2025. 551 funds tracked by Wall St. Rank hold HALO as of Q2 2025.

  • Roman Butler Fullerton & Co reported no remaining Halozyme position as of Q2 2025 after selling out during the quarter.
  • Roman Butler Fullerton & Co sold 6,751 Halozyme shares in Q2 2025, an estimated $414K.
  • Roman Butler Fullerton & Co first reported a position in Halozyme in Q1 2025 and held it in 1 quarter.
  • Roman Butler Fullerton & Co's Halozyme position peaked at $414K in Q1 2025.
  • 551 funds tracked by Wall St. Rank held Halozyme as of Q2 2025.

Based on Roman Butler Fullerton & Co's 13F filing for Q2 2025, filed 30 Jul 2025.